Synthesis and biological evaluation of chromone derivatives against triple-negative breast cancer cells

被引:2
|
作者
Islam, Rajibul [1 ]
Yan, Mock Phooi [1 ]
Yen, Khor Poh [2 ]
Rasol, Nurulfazlina Edayah [3 ,4 ]
Meng, Chan Kok [5 ]
Wai, Lam Kok [1 ]
机构
[1] Univ Kebangsaan Malaysia, Fac Pharm, Ctr Drug & Herbal Dev, Kuala Lumpur 50300, Malaysia
[2] Univ Kuala Lumpur, Royal Coll Med Perak, Fac Pharm & Hlth Sci, Ipoh 30450, Perak, Malaysia
[3] Univ Teknol MARA, Atta ur Rahman Inst Nat Prod Discovery, Puncak Alam Campus, Bandar Puncak Alam 42300, Selangor, Malaysia
[4] Univ Teknol MARA, Fac Appl Sci, Shah Alam 40450, Selangor, Malaysia
[5] Univ Kebangsaan Malaysia, Fac Hlth Sci, Ctr Toxicol & Hlth Risk Studies, Jalan Raja MudaAbdul Aziz, Kuala Lumpur 50300, Malaysia
关键词
Triple-negative breast cancer; Chromone; Anticancer; Multi-kinase inhibitor; INHIBITOR LY294002; KINASE; DOXORUBICIN; DESIGN; DEATH; PROLIFERATION; OPTIMIZATION; CHEMOTHERAPY; EXPRESSION; EFFICIENT;
D O I
10.1007/s00044-023-03048-4
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
This study described the bioactivity and the structure-activity relationship (SAR) of newly synthesized chromone derivatives against triple-negative breast cancer (TNBC) MDA-MB-231 cells. Among the compounds tested, C8 exerted a growth inhibitory effect on the TNBC-derived MDA-MB-231 cells with an IC50 value of 11.71 +/- 0.79 mu M. Results showed that it could promote apoptosis, sensitize TNBC MDA-MB-231 cells to doxorubicin (Dox) and inhibit multiple kinase activities with higher selectivity against PIM1 and PIM2 kinases. Molecular docking results revealed compound C8 engaged in several critical interactions with the important residues in PIM1 and PIM2 binding sites. This suggests that compound C8 possessed anticancer activity on TNBC cells potentially mediated by inhibition of multiple tyrosine kinases and kinases involved in cell-cycle regulation.
引用
收藏
页码:884 / 898
页数:15
相关论文
共 50 条
  • [21] Triple-Negative Breast Cancer
    Quyen D. Chu
    King, Tari
    Hurd, Thelma
    INTERNATIONAL JOURNAL OF BREAST CANCER, 2012, 2012
  • [22] Triple-negative breast cancer
    Chacon, Reinaldo D.
    Costanzo, Maria V.
    BREAST CANCER RESEARCH, 2010, 12
  • [23] Triple-negative breast cancer
    Stockmans, Gert
    Deraedt, Karen
    Wildiers, Hans
    Moerman, Philippe
    Paridaens, Robert
    CURRENT OPINION IN ONCOLOGY, 2008, 20 (06) : 614 - 620
  • [24] Triple-Negative Breast Cancer
    Foulkes, William D.
    Smith, Ian E.
    Reis-Filho, Jorge S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (20): : 1938 - 1948
  • [25] Evaluation of treatment outcomes of triple-negative breast cancer
    Cinkaya, Ahmet
    Akin, Mustafa
    Sengul, Adem
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2016, 12 (01) : 150 - 154
  • [26] Triple-negative breast cancer
    Bartsch R.
    Ziebermayr R.
    Zielinski C.C.
    Steger G.G.
    Wiener Medizinische Wochenschrift, 2010, 160 (7-8) : 174 - 181
  • [27] Triple-Negative Breast Cancer
    Liedtke, Cornelia
    Schmutzler, Rita
    Schneeweiss, Andreas
    Loibl, Sybille
    Thill, Marc
    Heitz, Florian
    BREAST CARE, 2010, 5 (05) : 359 - 363
  • [28] Triple-negative breast cancer
    Aschenbrenner, Diane S.
    AMERICAN JOURNAL OF NURSING, 2020, 120 (08) : 22 - 23
  • [29] Triple-negative breast cancer
    Reinaldo D Chacón
    María V Costanzo
    Breast Cancer Research, 12
  • [30] Efficacy of biological agents in metastatic triple-negative breast cancer
    Bramati, Annalisa
    Girelli, Serena
    Torri, Valter
    Farina, Gabriella
    Galfrascoli, Elena
    Piva, Sheila
    Moretti, Anna
    Dazzani, Maria Chiara
    Sburlati, Paola
    La Verde, Nicla Maria
    CANCER TREATMENT REVIEWS, 2014, 40 (05) : 605 - 613